Skip to main content
SpringerLink
Log in
Book cover

Cancer du sein pp 221–231Cite as

Cancers du sein avec HER2 surexprimé : quoi de neuf dans la prise en charge clinique ?

  • Conference paper

  • 246 Accesses

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92

    Article  PubMed  CAS  Google Scholar 

  2. Crone S, Zhao Y-Y, Fan L et al. (2002) Erb2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine 5: 459–65

    Article  CAS  Google Scholar 

  3. Seidman A, Hudis C, Pierri MK et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–21

    Article  PubMed  CAS  Google Scholar 

  4. Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22: 322–9

    Article  PubMed  CAS  Google Scholar 

  5. Sledge Gw, O’Neill A, Thor AD et al. (2001) Pilot trial of paclitaxel-Herceptin adjuvant therapy for early stage breast cancer (E2198). San Antonio Breast Cancer Symposium, Abst 4, 10–13 décembre

    Google Scholar 

  6. Carey A, Dees E, Sawyer L et al. (2002) Cardiotoxicity of trastuzumab given with weekly taxol immediately following 4AC as initial therapy for primary breast cancer American Society Clinical Oncology, Abst 253, 15–22 mai

    Google Scholar 

  7. Bianchi G, Albanell J, Eiermann W et al. (2003) Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9: 5944–51

    PubMed  CAS  Google Scholar 

  8. Trigo J, Climent M, Gil M et al. (2002) Cardiac safety and efficacy from a phase I trial of the liposomal doxorubicin TLC D-99 in combination with trastuzumab and paclitaxel in patients with HER2 positive locally advanced or metastatic breast cancer. Ann. Oncol 13: 51 (abst 183P)

    Article  Google Scholar 

  9. Maria Theodoulou, Susana M Campos, Gerald Batist et al. (2002) TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. American Society Clinical Oncology, Abst 216, 15–22 mai

    Google Scholar 

  10. Untch M, Eidtmann H, du Bois A et al. (2004) Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40: 988–97

    Article  PubMed  CAS  Google Scholar 

  11. Carney WP, Neumann R, Lipton A et al. (2004) Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 5: 105–16

    PubMed  CAS  Google Scholar 

  12. Molina R, Jo J, Filella X et al. (1999) C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients Anticancer Res 19: 2551–5

    CAS  Google Scholar 

  13. Classen S, Kopp R, Possinger K et al. (2002) Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol 23: 70–5

    Article  PubMed  CAS  Google Scholar 

  14. Colomer R, Montero S, Lluch A et al. (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356–62

    PubMed  CAS  Google Scholar 

  15. Meng S, Tripathy D, Shete S et al. (2004) HER-2 gene amplification can be acquired as breast cancer progresses. PNAS; 101: 9393–8

    Article  PubMed  CAS  Google Scholar 

  16. Gancberg D, Di Leo A, Cardoso F et al. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036–43

    Article  PubMed  CAS  Google Scholar 

  17. Ellis MJ, Coop A, Singh B et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–16

    PubMed  CAS  Google Scholar 

  18. Colomer R, Llombart A, Ramos M et al. (2001) Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study. San Antonio Breast Cancer Symposium, Abst 223: 10–13 décembre

    Google Scholar 

  19. Lipton A, Mouridsen H, Ali S (2001) Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. San Antonio Breast Cancer Symposium, Abst. 6, 10–13 décembre

    Google Scholar 

  20. Colomer R, Montero S, Lluch A et al. (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356–62

    PubMed  CAS  Google Scholar 

  21. Muller V, Witzel I, Luck HJ et al. (2004) Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat, 86: 9–18

    Article  PubMed  Google Scholar 

  22. Luftner DI, Schaller G, Henschke P et al. (2002) Evaluation of serum HER-2/neu for outcome assessment and monitoring of Herceptin plus combination chemotherapy in metastatic breast cancer. San Antonio Breast Cancer Symposium, Abst 427, 11–14 décembre

    Google Scholar 

  23. Kostler WJ, Schwab B, Singer CF et al. (2004) Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618–24

    Article  PubMed  Google Scholar 

  24. Lotz JP, Brault D, Gligorov J et al. (2003) Serial monitoring of serum HER-2 extracellular domain (H-ECD) during trastuzumab-paclitaxel chemotherapy (CT) for metastatic breast cancer (MBC) pts: Preliminary results from the French experience (HER.ME.S protocol). American Society Clinical Oncology, Abst 208, 31 mai–03 juin

    Google Scholar 

  25. Leyland-Jones B, Gelmon K, Ayoub JP et al. (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21: 3965–7

    Article  PubMed  CAS  Google Scholar 

  26. Tripathy D, Slamon DJ, Cobleigh M et al. (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22: 1063–70

    Article  PubMed  CAS  Google Scholar 

  27. Gelmon KA, Mackey J, Verma S et al. (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5: 52–8

    Article  PubMed  CAS  Google Scholar 

  28. Fountzilas G, Razis E, Tsavdaridis D et al. (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 4: 120–5

    PubMed  CAS  Google Scholar 

  29. Gennari R, Menard S, Fagnoni F et al. (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650–5

    Article  PubMed  CAS  Google Scholar 

  30. Van Pelt AE, Mohsin S, Elledge RM et al. (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4: 348–53

    PubMed  Google Scholar 

  31. Wenzel C, Hussian D, Bartsch R et al. (2004) Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 130: 400–4

    Article  PubMed  CAS  Google Scholar 

  32. Schneeweiss A, Kolay S, Aulmann S et al. (2004) Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib (Iressa, ZD 1839). Anticancer Drugs 15: 235–8

    Article  PubMed  CAS  Google Scholar 

  33. Moulder SL, Arteaga CL (2003) A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 4: 142–5

    PubMed  CAS  Google Scholar 

  34. Arteaga CL, O Neil A, Moulder SL et al. (2004) ECOG11000: a phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib (‘Iressa’) in patients with HER-2overexpressing mestastatic breast cancer. San Antonio Breast Cancer Symposium, Abst 25: 8–11 décembre

    Google Scholar 

  35. Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343–6

    Article  PubMed  CAS  Google Scholar 

  36. Arpino G, Weiss H, Wakeling AE et al. (2004) Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab and pertuzumab to block HER2 cross-talk with ER and restore Tamoxifen inhibition. San Antonio Breast Cancer Symposium, Abst 23: 8–11 decembre

    Google Scholar 

  37. Burris H, Hurwitz H, Dees C et al. (2003) A randomized multicenter, phase Ib study of the safety, biologis activity and clinical efficacy of the dual kinase inhibitor GW572018. San Antonio Breast Cancer Symposium, Abst 39: 3–6 décembre

    Google Scholar 

  38. Repp R, van Ojik HH, Valerius T et al. (2003) Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 89: 2234–43

    Article  PubMed  CAS  Google Scholar 

  39. Dang CT, D’Andrea GM, Moynahan ME et al. (2004) Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 10: 5754–61

    Article  PubMed  CAS  Google Scholar 

  40. Nagata Y, Lan KH, Zhou X et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–27

    Article  PubMed  CAS  Google Scholar 

  41. Pandolfi PP (2004) Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337–8

    Article  PubMed  CAS  Google Scholar 

  42. Argiris A, Wang CX, Whalen SG et al. (2004) Synergistic interactions between tamoxifen and trastuzumab. Clin Cancer Res; 10: 1409–20

    Article  PubMed  CAS  Google Scholar 

  43. Ropero S, Menendez JA, Vazquez-Martin A et al. (2004) Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86: 125–37

    Article  PubMed  CAS  Google Scholar 

  44. Shou J, Massarweh S, Osborne K et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96: 926–35

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Claudius Regaud, 20-24, rue du Pont-Saint-Pierre, 31052, Toulouse Cedex

    H. Roché

Authors
  1. H. Roché
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this paper

Cite this paper

Roché, H. (2006). Cancers du sein avec HER2 surexprimé : quoi de neuf dans la prise en charge clinique ?. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/2-287-31109-2_12

Download citation

  • DOI: https://doi.org/10.1007/2-287-31109-2_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25174-0

  • Online ISBN: 978-2-287-31109-3

Publish with us

Policies and ethics

Search

Navigation